Related Experiment Video

Updated: Feb 25, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

793

Human epidermal growth factor (Her-2) in gastric and colorectal adenocarcinoma

Asma Shabbir1, Muhammad Asif Qureshi2, Talat Mirza2

  • 1Jinnah Sindh Medical University, Karachi.

JPMA. the Journal of the Pakistan Medical Association
|August 4, 2017
PubMed

Insights

Human epidermal growth factor (Her-2) is a potential therapeutic target for gastrointestinal cancers. This review examines Her-2 expression in gastric and colorectal cancers to clarify its role in treatment.

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Gastrointestinal (GIT) malignancies pose significant health challenges, often diagnosed at advanced stages.
  • Current chemotherapies have limited efficacy in curing unresectable GIT diseases, necessitating novel therapeutic targets.

Purpose of the Study:

  • To review the literature on human epidermal growth factor receptor 2 (Her-2) expression in gastric and colorectal adenocarcinomas.
  • To evaluate the correlation of Her-2 expression with various parameters in these cancers.
  • To discuss the potential of anti-Her-2 therapies in treating gastrointestinal malignancies.

Main Methods:

  • Literature search of the United States National Library of Medicine (NLM) and Pubmed Central databases.
  • Systematic review and synthesis of available studies on Her-2 expression and anti-Her-2 therapy in GIT cancers.

Main Results:

  • Her-2 expression in gastric and colorectal adenocarcinomas is a subject of ongoing debate.
  • Data on the correlation between Her-2 expression and clinical parameters requires further clarification.
  • Evidence supporting the use of anti-Her-2 agents in GIT malignancies is under investigation.

Conclusions:

  • Clarifying Her-2 expression is crucial for developing targeted therapies in gastrointestinal cancers.
  • Further research is needed to establish the efficacy and role of anti-Her-2 treatments in gastric and colorectal malignancies.
Keywords:
Her-2, Gastrointestinal neoplasms, Adenocarcinoma.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K